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Abstract
Background: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene.
Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90–95
% of mutations are either BRAFV600E or BRAFV600K. Specific BRAF inhibitors such as dabrafenib and vemurafenib are
the mainstays of treatment in patients with metastatic BRAF-mutant malignant melanomas. The third most
common BRAF mutation is V600R, which also leads to increased BRAF signaling. Although evidence exists about the
activity of dabrafenib and vemurafenib in patients with the BRAFV600R mutation, these patients have been
systematically excluded from recent trials with targeted therapies.
Case presentation: Here, we report the positive results in terms of survival and quality of life obtained with
dabrafenib in an 80-year-old Caucasian male patient with a Charlson Comorbidity Index of 8 diagnosed with
metastatic malignant melanoma harboring the BRAFV600R mutation. Our patient was treated with dabrafenib for 7
months with minimal toxicity. We also report exploratory analyses of circulating tumor DNA during targeted
treatment. Interestingly, the mutation was not detected after starting treatment and became detectable before
radiological disease progression.
Conclusions: Our report suggests that (1) a relevant benefit can be obtained with a BRAF inhibitor in real-world
patients with a malignant melanoma harboring a BRAFV600R mutation, and that (2) circulating tumor DNA detection
might be of help in assessing tumor burden in everyday clinical practice. The results reported here should
encourage the inclusion of patients with BRAFV600R-mutated malignant melanomas in future prospective clinical
trials with BRAF inhibitors.
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Background
The BRAF gene is localized at 7q34 and encodes a family
of protein kinases involved in cell signal transduction
through the mitogen-activated protein kinase MAPK
(Ras/Raf/MEK/ERK) pathway, which mainly affects cell
differentiation and proliferation [1–4]. Activation of the
MAPK pathway, generally through point mutations in
one or more of its components, has been associated with
several diseases, such as cardiofaciocutaneous syndrome,
Erdheim-Chester disease, Langerhans cell histiocytosis,
and Noonan syndrome [2–4]. BRAF mutations have also
been associated with malignancies, such as melanoma,
thyroid carcinoma, and colorectal carcinoma [5, 6].
Identification of BRAF as an actionable target in ad-
vanced malignant melanoma (MM) has led to a dramatic
change in the treatment scope of this disease [7]. Approxi-
mately 50 % of MMs harbor mutations in amino acid 600
of the BRAF gene [5]. These are usually amino acid substi-
tutions that result in a protein conformation change that
leads to constitutionally elevated kinase activity [6]. Over
90 % of activating mutations are either valine-glutamate
(BRAFV600E) or valine-lysine (BRAFV600K) substitutions,
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which account for 75 and 15 %, respectively [8]. Dabrafe-
nib and vemurafenib were the first BRAF inhibitors to
show a clear benefit over chemotherapy treatment in
patients with BRAF-mutated metastatic MM [9, 10].
Although initially designed to target the BRAFV600E mu-
tation, early studies of dabrafenib and vemurafenib also
included BRAFV600K-mutated melanoma cases, and
showed a clinical benefit in this subset of patients [7, 11,
12]. The third most frequent BRAF mutation is V600R,
accounting for 1–5 % depending on the series and sequen-
cing technique [8, 13, 14]. Patients with this rare mutation
were excluded from pivotal trials with BRAF inhibitors
and have also been excluded from the more recent BRAF/
MEK dual inhibition trials [15, 16]. However, activity of
BRAF inhibitors in this context has been reported in
BRAFV600R-mutated melanoma cell lines [17] and in a
small Australian patient series [18].
Here, we present a case of durable clinical benefit with
the use of dabrafenib in an 80-year-old patient with moder-
ate comorbidity diagnosed with metastatic MM harboring
the BRAFV600R mutation. Additionally, due to the emer-
gence of circulating tumor (ct) DNA as a promising bio-
marker for assessing tumor burden and treatment response
[19], we collected serial plasma samples and report explora-
tory analyses of ctDNA during our patient’s treatment.
Case presentation
Our patient was an 80-year-old Caucasian man with a
history of arterial hypertension, dyslipidemia, hyperurice-
mia, and hypothyroidism, for which he was being medically
treated. He did not drink alcohol and was a former smoker
of cigarettes. Our patient had no familiar history of cancer.
He had undergone a right nephrectomy in 2002 due to a
spontaneous retroperitoneal hematoma and consequently
had chronic renal insufficiency (usual creatinine levels of
1.6–2.0 mg/dL and a glomerular filtration rate of 40 mL/
min). He had no history of cognitive impairment or demen-
tia and retained full autonomy in his daily activities and
personal care needs. In June 2010 he had undergone surgi-
cal resection of a 26 mm-diameter pigmented lesion on his
right pre-auricular region. The pathology report disclosed
an ulcerated MM with a Breslow index of 0.7 mm and a
Clark level of III (pT1b, Stage IB) [20].
Clinical findings
When first evaluated by our Oncology Department, our
patient presented with moderate asthenia that limited his
daily activity, without other relevant clinical symptoms. A
physical examination did not detect any relevant findings
(Eastern Cooperative Oncology Group [ECOG] perform-
ance status of 1). A full-body CT scan revealed the pres-
ence of pulmonary and hepatic nodules (Fig. 1a). No brain
metastases were detected. A complete blood work-up pro-
duced the following results (normal range values in
parenthesis): glucose 87 mg/dL (75–115), urea 70 mg/dL
(10–50), serum creatinine 1.76 mg/dL (0.6–1.4), glomeru-
lar filtration rate 40 mL/min/1.73m2 (>60), urate 7.4 mg/
dL (3.4–7.0), sodium 138 mmol/L (135–146), potassium
4.7 mmol/L (3.5–5.1), total bilirubin 0.43 mg/dL (0.2–1.2),
aspartate aminotransferase (AST) 59 UI/L (10–38), ala-
nine aminotransferase (ALT) 52 UI/L (7–41), gamma-
glutamyltransferase (GGT) 363 UI/L (8–61), alkaline
phosphatase 204 UI/L (40–129), serum calcium 9 mg/dL
(8.5–10.5), serum albumin 3.9 g/dL (3.8–5.1), hemoglobin
12.1 g/dL (13–17), total leukocyte count 10.1 × 103/μL
(4–11), neutrophil count 6.5 × 103/μL (2.5–8.2), lympho-
cyte count 1.6 × 103/μL (1.5–5), and total platelet count
290 × 103/μL (150–450). It is important to highlight that
his LDH levels were elevated (820 UI/L) [21].
Diagnostic assessment and therapeutic intervention
Our patient underwent a core-needle biopsy of the largest
hepatic lesion in segment IVb without any complications.
Pathology results were positive for MM and therefore the
biopsy specimen was studied for mutations in BRAF, KIT,
and NRAS genes using the cobas 4800 Test (cobas® 4800
BRAF V600 Mutation Test; Roche Molecular Diagnostics,
Inc., Pleasanton, CA, USA) and Sanger sequencing for the
three genes. The V600R mutation was detected in the
BRAF gene (Fig. 1b); no mutations were detected in the
KIT or NRAS genes. In August 2013, our patient was
started on dabrafenib treatment in a compassionate-use
program at the initial standard dose of 150 mg orally every
12 h.
Follow-up and outcome
Our patient’s asthenia showed a rapid recovery, with rapid
improvement in his ECOG score from 1 to 0 in the first
month of treatment. In subsequent evaluations, only min-
imal cutaneous toxicity appeared (beard alopecia and the
appearance of several milium cysts, see Fig. 1c). Several
warty lesions appeared, none of them compatible with
keratoacanthoma or cutaneous squamous-cell carcinoma.
His first radiological evaluation by CT, 2.5 months after
starting treatment, showed a partial reduction of both the
hepatic and pulmonary lesions, which was considered to
indicate stable disease by Response Evaluation Criteria In
Solid Tumors (RECIST) 1.1 criteria [22]. This radiologic
response was maintained in a second CT evaluation after
5 months of therapy (Fig. 1d).
Seven months after the start of treatment, our patient
presented with pneumonia and was admitted to our Oncol-
ogy ward. During his stay at our hospital, a CT scan showed
hepatic and retroperitoneal progression, as well as the
appearance of pericardial and pleural effusions (Fig. 1e).
Additionally, MRI detected multiple bilateral brain metasta-
ses (Fig. 1f). Treatment with dabrafenib was stopped. His
brain lesions were considered unresectable, and our patient
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received whole brain radiotherapy. After this, he main-
tained an ECOG performance status of 2 and was thus
deemed non-eligible for further treatments. He was referred
to our palliative care unit and received regular in-home
visits. Our patient died in September 2014.
Exploratory ctDNA analysis
As part of a research project at our center, plasma sam-
ples were periodically extracted during therapy. For this
patient, five plasma samples were available for BRAF
mutation analysis. Plasma was obtained from 8 mL of
peripheral blood collected in tubes with EDTA as the
anticoagulant. The plasma was separated within 5 h by
centrifugation at room temperature for 15 min at 3200
rpm, then aliquoted and stored at −80 °C. ctDNA was
extracted from the plasma using the QIAamp Circulat-
ing Nucleic Acid Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. The BRAFV600R
mutation was targeted in a real-time 7500 fast PCR (Life
Technologies, Foster City, CA, USA) using a competitive
allele-specific TaqMan (cast-PCR) assay specifically de-
signed for this mutation (Life Technologies).
In the samples extracted on 13 September 2013 and 7
January 2014, the mutation was undetectable. In the
samples extracted on 30 January and 13 March 2014
(the latter coinciding with the CT scan showing disease
progression), the tumor’s known BRAFV600R mutation
was detected. The mutation was further detected in the
samples extracted in April and May 2014.
Discussion
The BRAFV600R mutation occurs in up to 5 % of MM cases
and it results in the substitution of valine by arginine at
amino acid 600 of the BRAF gene. Similar to BRAFV600E
and BRAFV600K, BRAFV600R causes an increase in BRAF





Fig. 1 Timeline. The black arrow represents time from diagnosis of metastatic disease until patient’s death. The orange arrow represents the duration
of treatment with dabrafenib (7.1 months). Along the arrows, the − and + symbols represent the time points at which the plasma BRAFV600R mutation
was negative and positive, respectively. a Initial CT scans (21 June 2013) showing hepatic (top) and pulmonary (bottom) lesions. b Representation
of V600R mutation detected by Sanger sequencing. The black arrow points to the nucleotide changes. c Appearance of milium cysts (white arrow)
secondary to dabrafenib treatment. d CT scans (8 January 2014) showing the radiological response is maintained after 5 months of treatment. The
pictures correspond to the same lesions shown in a. e CT scans (17 March 2014) showing disease progression after 7.1 months of dabrafenib
treatment. Top picture shows a new right adrenal mass and the bottom picture reveals the appearance of pericardial and pleural effusions. f Brain MRI
showing multiple brain metastases (1 April 2014)
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clinical activity of BRAF inhibitors in patients with tumors
harboring the BRAFV600R mutation is scarce and comes
from case reports and series of cases. Klein et al. [18] have
reported the largest series of patients with BRAFV600R-mu-
tant tumors treated with BRAF inhibitors. Five out of nine
patients in this series showed a partial response and one
patient was maintained for 10.4 months on dabrafenib
treatment before showing disease progression. In the same
year, van den Brom et al. [24] reported clinical activity of
vemurafenib in a patient with a BRAFV600R-mutated MM
with a solitary brain metastasis. They observed a significant
improvement in their patient’s neurological symptoms and
demonstrated a partial response of the brain lesion by
RECIST criteria.
Our patient was evaluated as an 80-year-old man with
an excellent quality of life, with an ECOG performance
status of 1 with moderate comorbidity (age-adjusted
Charlson Index of 8) and a poor prognosis according to
total LDH levels [21]. At our institution, BRAF muta-
tions are initially assessed through the cobas 4800 Test
and all cases are further confirmed by Sanger sequen-
cing. At the time of our patient’s diagnosis, approval of
dabrafenib or vemurafenib in Spain by the national regu-
latory agencies (AEMPS) was still pending. In our public
health system, the only authorized first-line treatments
were chemotherapeutic agents such as dacarbazine or
fotemustine. Clinical benefits with chemotherapy are
only seen in a limited number of patients. In the most
recent trials in patients with BRAF-mutated MM being
treated with dacarbazine in the control arm, response
rates were around 5–10 % and progression-free survival
(PFS) times were less than 2 months [7, 10, 25]. After
discussing the benefits and risks of chemotherapy versus
a targeted agent with the patient and his family, a deci-
sion was made for a targeted therapy. We were able to
obtain dabrafenib in a compassionate-use protocol from
GlaxoSmithKline. In the pivotal trial of dabrafenib [10],
elderly patients were also included, and the maximum
age was 93 in the experimental arm. Also, dabrafenib is
mainly eliminated in the feces and thus needed no dose
adjustment considering our patient’s renal function.
As reported above, our patient’s tolerance to the treat-
ment was excellent, with minimal cutaneous toxicity. He
stayed on the treatment for 7.1 months, which is above
the median PFS observed in the BREAK-3 trial [10], and
he lived for 15 months.
Non-BRAFV600E mutations have been associated with
increasing age, and clinical differences have been re-
ported regarding the primary site of the tumor between
BRAFV600E- and BRAFV600K-mutated MMs [26]. Inter-
estingly, the nine BRAFV600R-mutated MMs reported by
Klein and collaborators [18] share some clinical features
with our patient. Eight of their nine patients were men
and four of them were older than 70 years. Primary
lesions were in the scalp in four patients and were ulcer-
ated in six of them. However, the numbers are too small
to draw conclusions.
Finally, we performed an exploratory analysis of
ctDNA as a biomarker during the targeted treatment.
Although technical and economical limitations preclude
us from using this method efficiently in our daily clinical
practice, it shows great promise as a means for early
diagnosis and tumor-burden monitoring [19, 27]. All our
analyses were performed retrospectively within an inves-
tigational trial and were not used for treatment deci-
sions. In our patient, the mutation was undetectable
during dabrafenib treatment and response, becoming de-
tectable before radiologically detected disease progres-
sion. Although it is tempting, no robust conclusions can
be drawn from these observations, since we had no
available plasma at the time of diagnosis and we did not
explore other mutations apart from the BRAFV600R.
However, this finding is coherent with the knowledge
that, in MM with acquired resistance to BRAF inhibi-
tors, the original BRAF mutation persists [28].
Conclusions
This case report highlights (1) the benefits that can be ob-
tained with a BRAF inhibitor in real-world patients with
MM harboring the BRAFV600R mutation, and (2) the poten-
tial application of emerging new techniques such as ctDNA
detection in our everyday clinical practice. In our opinion,
the possibility of on-site molecular testing and the availabil-
ity of targeted treatment greatly impacted our patient’s out-
come and quality of life.
Finally, patients with an MM harboring a BRAFV600R mu-
tation should not be excluded from randomized clinical tri-
als (RCTs). This is of greatest importance in countries with
a public health system, because local regulatory agencies
strictly rely on RCT data to approve new treatments for the
different subsets of patients.
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